2022
Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites.
Sun TY, Zhao L, Van Hummelen P, Martin B, Hornbacker K, Lee H, Xia LC, Padda SK, Ji HP, Kunz P. Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites. Endocrine Related Cancer 2022, 29: 665-679. PMID: 36165930, PMCID: PMC10043760, DOI: 10.1530/erc-22-0015.Peer-Reviewed Original ResearchConceptsHigh-grade neuroendocrine neoplasmsDiverse primary sitesG3 NENNeuroendocrine neoplasmsPrimary siteHigh tumor mutation burdenExploratory genomic analysisTumor mutation burdenPoor survival outcomesMutations/MbDifferent primary sitesOrgan of originRare cancer typesSurvival outcomesWorse prognosisRare tumorCell cycling pathwaysMutation burdenTherapeutic implicationsClinical standpointSomatic copy number alterationsCopy number alterationsCancer typesNeoplasmsUpregulation of oncogenes
2020
Comprehensive genomic sequencing of high-grade neuroendocrine neoplasms.
Sun T, Van Hummelen P, Martin B, Xia C, Lee H, Zhao L, Hornbacker K, Ji H, Kunz P. Comprehensive genomic sequencing of high-grade neuroendocrine neoplasms. Journal Of Clinical Oncology 2020, 38: 624-624. DOI: 10.1200/jco.2020.38.4_suppl.624.Peer-Reviewed Original Research
2019
Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.
Chan D, Bergsland E, Chan J, Gadgil R, Halfdanarson T, Hornbacker K, Kelly V, Kunz P, McGarrah P, Raj N, Reidy D, Thawer A, Whitman J, Wu L, Singh S. Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review. Journal Of Clinical Oncology 2019, 37: 321-321. DOI: 10.1200/jco.2019.37.4_suppl.321.Peer-Reviewed Original ResearchTreatment failureG3 NENRetrospective reviewDose reduction/discontinuationBest radiological responseLocal pathology reportsMulticentre retrospective reviewOptimal systemic treatmentProspective confirmatory trialMedian TTFMulticenter retrospective reviewReduction/discontinuationBetter response rateViable treatment optionGastroenteropancreatic NENRadiologic responseStable diseasePrimary endpointRECIST criteriaAdverse eventsOverall survivalPartial responseProgressive diseaseRadiological responseSystemic treatment